vs

Side-by-side financial comparison of Cardio Diagnostics Holdings, Inc. (CDIO) and MYRIAD GENETICS INC (MYGN). Click either name above to swap in a different company.

MYRIAD GENETICS INC is the larger business by last-quarter revenue ($209.8M vs $3.6K, roughly 59015.5× Cardio Diagnostics Holdings, Inc.). On growth, MYRIAD GENETICS INC posted the faster year-over-year revenue change (-0.4% vs -21.2%). Over the past eight quarters, MYRIAD GENETICS INC's revenue compounded faster (1.9% CAGR vs -52.8%).

Cardio Diagnostics Holdings, Inc. is a precision cardiovascular healthcare company that develops and commercializes integrated genetic and epigenetic diagnostic tests for early detection of coronary heart disease, heart failure, and other cardiovascular conditions. It primarily serves healthcare providers, clinical laboratories, and patients across the United States, focusing on delivering accessible, personalized cardiovascular care solutions.

Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new products that assess an individual's risk for developing disease later in life, identify a pati...

CDIO vs MYGN — Head-to-Head

Bigger by revenue
MYGN
MYGN
59015.5× larger
MYGN
$209.8M
$3.6K
CDIO
Growing faster (revenue YoY)
MYGN
MYGN
+20.8% gap
MYGN
-0.4%
-21.2%
CDIO
Faster 2-yr revenue CAGR
MYGN
MYGN
Annualised
MYGN
1.9%
-52.8%
CDIO

Income Statement — Q4 2025 vs Q4 2025

Metric
CDIO
CDIO
MYGN
MYGN
Revenue
$3.6K
$209.8M
Net Profit
Gross Margin
70.0%
Operating Margin
-2.7%
Net Margin
Revenue YoY
-21.2%
-0.4%
Net Profit YoY
3.6%
EPS (diluted)
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CDIO
CDIO
MYGN
MYGN
Q4 25
$3.6K
$209.8M
Q3 25
$2.9K
$205.7M
Q2 25
$7.5K
$213.1M
Q1 25
$940
$195.9M
Q4 24
$4.5K
$210.6M
Q3 24
$6.6K
$213.3M
Q2 24
$7.9K
$211.5M
Q1 24
$15.9K
$202.2M
Net Profit
CDIO
CDIO
MYGN
MYGN
Q4 25
Q3 25
$-1.7M
$-27.4M
Q2 25
$-1.7M
$-330.5M
Q1 25
$-1.6M
$-100.0K
Q4 24
Q3 24
$-1.4M
$-22.1M
Q2 24
$-1.3M
$-36.7M
Q1 24
$-4.2M
$-26.0M
Gross Margin
CDIO
CDIO
MYGN
MYGN
Q4 25
70.0%
Q3 25
69.9%
Q2 25
71.2%
Q1 25
68.5%
Q4 24
71.7%
Q3 24
70.2%
Q2 24
69.6%
Q1 24
68.1%
Operating Margin
CDIO
CDIO
MYGN
MYGN
Q4 25
-2.7%
Q3 25
-59950.9%
-11.3%
Q2 25
-22457.5%
-154.5%
Q1 25
-173463.8%
-14.8%
Q4 24
-18.6%
Q3 24
-21412.9%
-9.4%
Q2 24
-16295.6%
-17.3%
Q1 24
-26105.3%
-13.8%
Net Margin
CDIO
CDIO
MYGN
MYGN
Q4 25
Q3 25
-60053.8%
-13.3%
Q2 25
-22517.7%
-155.1%
Q1 25
-173943.0%
-0.1%
Q4 24
Q3 24
-21467.6%
-10.4%
Q2 24
-16365.9%
-17.4%
Q1 24
-26140.0%
-12.9%
EPS (diluted)
CDIO
CDIO
MYGN
MYGN
Q4 25
$-0.09
Q3 25
$-0.98
$-0.29
Q2 25
$-0.97
$-3.57
Q1 25
$-0.97
$0.00
Q4 24
$-0.47
Q3 24
$-1.73
$-0.24
Q2 24
$-1.71
$-0.41
Q1 24
$-5.93
$-0.29

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CDIO
CDIO
MYGN
MYGN
Cash + ST InvestmentsLiquidity on hand
$149.6M
Total DebtLower is stronger
$119.9M
Stockholders' EquityBook value
$7.0M
$368.0M
Total Assets
$7.8M
$706.6M
Debt / EquityLower = less leverage
0.33×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CDIO
CDIO
MYGN
MYGN
Q4 25
$149.6M
Q3 25
$145.4M
Q2 25
$74.4M
Q1 25
$91.8M
Q4 24
$102.4M
Q3 24
$99.9M
Q2 24
$97.3M
Q1 24
$104.3M
Total Debt
CDIO
CDIO
MYGN
MYGN
Q4 25
$119.9M
Q3 25
$119.5M
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
CDIO
CDIO
MYGN
MYGN
Q4 25
$7.0M
$368.0M
Q3 25
$8.2M
$372.8M
Q2 25
$9.7M
$388.1M
Q1 25
$11.4M
$704.9M
Q4 24
$9.6M
$701.1M
Q3 24
$3.7M
$731.7M
Q2 24
$3.1M
$740.5M
Q1 24
$3.0M
$760.0M
Total Assets
CDIO
CDIO
MYGN
MYGN
Q4 25
$7.8M
$706.6M
Q3 25
$8.8M
$728.1M
Q2 25
$10.4M
$677.3M
Q1 25
$12.3M
$1.0B
Q4 24
$10.6M
$1.0B
Q3 24
$4.5M
$1.1B
Q2 24
$4.0M
$1.1B
Q1 24
$4.3M
$1.1B
Debt / Equity
CDIO
CDIO
MYGN
MYGN
Q4 25
0.33×
Q3 25
0.32×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CDIO
CDIO
MYGN
MYGN
Operating Cash FlowLast quarter
$-5.7M
$10.6M
Free Cash FlowOCF − Capex
$-5.9M
FCF MarginFCF / Revenue
-166361.5%
Capex IntensityCapex / Revenue
5269.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-10.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CDIO
CDIO
MYGN
MYGN
Q4 25
$-5.7M
$10.6M
Q3 25
$-1.4M
$21.1M
Q2 25
$-1.6M
$-13.6M
Q1 25
$-1.4M
$-16.3M
Q4 24
$-5.0M
$6.6M
Q3 24
$-1.2M
$700.0K
Q2 24
$-1.2M
$2.6M
Q1 24
$-1.2M
$-18.6M
Free Cash Flow
CDIO
CDIO
MYGN
MYGN
Q4 25
$-5.9M
Q3 25
$-1.6M
Q2 25
$-1.6M
Q1 25
$-1.4M
Q4 24
$-5.2M
Q3 24
$-1.2M
Q2 24
$-1.4M
Q1 24
$-1.3M
FCF Margin
CDIO
CDIO
MYGN
MYGN
Q4 25
-166361.5%
Q3 25
-54509.7%
Q2 25
-21273.1%
Q1 25
-149562.6%
Q4 24
-115422.6%
Q3 24
-17942.3%
Q2 24
-17513.3%
Q1 24
-7866.9%
Capex Intensity
CDIO
CDIO
MYGN
MYGN
Q4 25
5269.1%
Q3 25
5703.5%
Q2 25
250.1%
Q1 25
615.6%
Q4 24
4759.9%
Q3 24
353.3%
Q2 24
2133.4%
Q1 24
125.5%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons